生物制药公司Ultragenyx Pharmaceutical Inc近日发布预测，到2027年，其研发支出预计将比2025年水平减少38%，相当于约2.8亿美元。这一调整反映了公司在完成关键临床试验后，研发管线将进入相对成熟的阶段。随着多个候选药物进入商业化准备期，公司计划将资源更多投向市场推广和产品上市工作。此次研发支出的战略性缩减，有望为公司在未来几年实现盈利增长创造有利条件。
生物制药公司Ultragenyx Pharmaceutical Inc近日发布预测，到2027年，其研发支出预计将比2025年水平减少38%，相当于约2.8亿美元。这一调整反映了公司在完成关键临床试验后，研发管线将进入相对成熟的阶段。随着多个候选药物进入商业化准备期，公司计划将资源更多投向市场推广和产品上市工作。此次研发支出的战略性缩减，有望为公司在未来几年实现盈利增长创造有利条件。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.